Forte Biosciences Inc Stock Price, News & Analysis

Forte Biosciences, Inc. (NASDAQ: FBRX) announced an equity inducement award for purchasing 90,000 shares of common stock to a new non-executive employee. This grant, approved by the Compensation Committee, serves as a material inducement for employment and will vest over four years. The award aligns with the terms of Forte's 2021 Equity Incentive Plan. Forte is a clinical-stage biopharmaceutical company focused on developing FB-401 for treating inflammatory skin diseases, including pediatric atopic dermatitis, with ongoing clinical trials demonstrating safety and activity across various age groups.

Forte Biosciences, Inc. (NASDAQ: FBRX) announced the issuance of an equity inducement award to a new non-executive employee, granting options to purchase 15,000 shares of common stock. This award is a requirement of NASDAQ Listing Rule 5635(c)(4) and will vest over four years. The company, focused on developing FB-401 for inflammatory skin diseases, has completed a Phase 1/2a study showing safety and efficacy in patients aged 3 and older. A multi-center, placebo-controlled trial of FB-401 is ongoing.

Forte Biosciences, Inc. (NASDAQ: FBRX) announced the issuance of an equity inducement award of 25,000 shares to a new non-executive employee. This grant aims to encourage employment and vests over four years. The company, focused on developing FB-401 for treating inflammatory skin diseases, has completed a Phase 1/2a study showing safety and activity across various age groups. A Phase 2 clinical trial has also been initiated for pediatric and adult atopic dermatitis patients. The company emphasizes that forward-looking statements may differ from actual outcomes due to various risks.

Forte Biosciences, Inc. (NASDAQ: FBRX) reported its first quarter 2021 results on May 10, highlighting significant progress in its clinical trial for FB-401, targeting atopic dermatitis. The trial has completed enrollment with 154 subjects, with topline results expected in Q3 2021. The company ended Q1 2021 with approximately $54.8 million in cash, sufficient for operations over the next year. Operating expenses rose due to increased R&D and administrative costs, leading to a net loss of $4.8 million, or $0.36 per share.

Forte Biosciences, Inc. (NASDAQ: FBRX) will disclose its first quarter 2021 results and provide a business update on May 10, 2021. The conference call will take place at 4:30 PM Eastern Time, accessible via phone or webcast. Forte is focused on developing FB-401, a live biotherapeutic for treating inflammatory skin diseases, particularly atopic dermatitis. A Phase 1/2a study has shown promising safety and efficacy across age groups. However, the company notes the potential risks associated with clinical development and obtaining necessary capital.

Forte Biosciences, Inc. (NASDAQ: FBRX) announced its fourth quarter and full year 2020 results on March 24, 2021. The company completed enrollment of 154 subjects in its clinical trial for FB-401, which received FDA Fast Track designation. Additionally, Forte raised $46 million through a public offering in November. As of December 31, 2020, the company's cash and cash equivalents totaled $58.8 million, sufficient for operations for at least 12 months. R&D expenses surged to $10 million, driven by clinical development costs, while 2020 losses per share were reported at $6.32.

Forte Biosciences, Inc. (NASDAQ: FBRX) will announce its 4Q and full-year 2020 results on March 24, 2021, at 8:30 AM ET, accompanied by a business update. The conference call can be accessed via phone or a webcast link provided in the release. Forte is developing FB-401, a live biotherapeutic for inflammatory skin diseases, with a clinical trial for pediatric atopic dermatitis currently in progress. This initiative addresses a significant unmet medical need in this demographic.

Forte Biosciences, Inc. (NASDAQ: FBRX) announced that CEO Paul Wagner, Ph.D., will present at the Chardan Annual Microbiome Medicines Summit on March 8, 2021. A webcast of the presentation will be available at this link at 1:00 PM Eastern Time, with a replay accessible until March 15, 2021. Forte is developing a live biotherapeutic, FB-401, for treating inflammatory skin diseases like atopic dermatitis in patients aged 2 and older, addressing significant unmet needs in this area.

Forte Biosciences, Inc. (NASDAQ: FBRX) announced that CEO Paul Wagner, Ph.D., will present at the Cowen Annual Health Care Conference on March 1, 2021. A webcast is scheduled for the same day at 4 PM ET, accessible via the company's website. Forte is developing FB-401, a live biotherapeutic for inflammatory skin diseases, targeting atopic dermatitis with significant unmet needs, particularly in pediatric patients. FB-401 has completed Phase 1/2a trials, and a new multi-center trial for various age groups is underway, expected to enhance treatment options.